

**NOTICE OF NEW HAMPSHIRE MEDICAID FEE FOR SERVICE  
DRUG UTILIZATION REVIEW BOARD  
PUBLIC HEARING  
October 15, 2024**

The New Hampshire Drug Utilization Review (DUR) Board invites you to attend a public hearing at 1:00 p.m., on October 15, 2024 in the Brown Building Conference Room 468 **and** via Teams Webinar. The DUR meeting will immediately follow this public hearing. The Teams Webinar information will be available 1 week prior to the DUR meeting at <https://nh.magellanrx.com/>.

The purpose of the public hearing is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid Fee for Service pharmacy prior authorization criteria and PDL additions.

The public hearing will begin at 1:00 p.m. and end no later than 2:00 p.m. The DUR meeting will begin at or before 2:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the proposed prior authorization criteria and PDL additions. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. The public comment hearing is scheduled for an hour; therefore speakers will be limited to 3 – 5 minutes depending on the number of preregistered speakers. Speaking material will be limited to the items on the agenda.

Written material may also be submitted by the public for DUR Board consideration, if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

If accommodations are needed for communication access such as interpreters, CART (captioning), assistive listening devices, or other auxiliary aids and/or services, please contact Margaret ‘Peg’ Clifford at (603) 271-9098 by October 1, 2024. At least 5 business days advance notice is requested in order to assure availability; requests made fewer than 5 days prior to the event will attempt to be accommodated but cannot be guaranteed.

**DRUG UTILIZATION REVIEW BOARD MEETING  
October 15, 2024  
Meeting Agenda**

- I. Introductions and Welcome to Board Members
  
- II. Old Business
  - A. Minutes – 5/7/2024 review
  - B. Sickle Cell Gene Therapy Criteria – Prior Therapy Data
  - C. Opioid Naïve Quantity Limit
  
- III. New Business
  - A. DUR Business Operations
    - 1. Overview of Drug Utilization Patterns for the New Hampshire Medicaid Fee-for Service Program

- a. Prospective DUR Reports
- b. Utilization Reports
- c. Retrospective DUR Reports

B. COVID-19 Status Update

C. Review of Current Clinical Prior Authorization Criteria with Proposed Changes

1. Calcitonin Gene-Related Peptide (CGRP) Inhibitor
2. Convenience Kits
3. Dupixent®
4. Elevidys
5. Juxtapid®
6. Long-Acting Opioid Analgesics
7. Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
8. Movement Disorders
9. Skin Disorders
10. Systemic Immunomodulators
11. Topical Retinoids
12. Wakix®

D. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes

1. Benign Prostatic Hyperplasia
2. Codeine for Pediatric Use
3. Hepatitis C
4. Hyaluronic Acid Derivatives
5. Rho Kinase Inhibitor
6. Stromectol®

E. Proposal of Clinical Prior Authorization to Retire

1. Hemgenix®

F. Proposal of New Clinical Prior Authorization Criteria

1. Cholestatic Pruritis
2. Epidermolysis Bullosa
3. Hemophilia B Gene Therapy
4. Primary Biliary Cholangitis

IV. Adjourn

Further information regarding the agenda items may be obtained after October 1, 2024. Notice of intent to testify at the public hearing, and/or submittal of written comments, should be directed to Margaret 'Peg' Clifford, NH Department of Health and Human Services, 129 Pleasant Street, Concord, NH, 03301, (603) 271-9098, or e-mail at: [margaret.clifford@dhhs.nh.gov](mailto:margaret.clifford@dhhs.nh.gov).